Sickle cell intrahepatic cholestasis (SCIC) is a rare but fatal complication of sickle cell disease. It is found mainly in homozygous sickle cell disease. To date, there are no standard diagnostic criteria or well-established therapeutic approaches to this condition. Herein, we report this case of a 48-year-old man with sickle cell anemia and a total bilirubin of 78.5 mg/dL without evidence of extrahepatic biliary obstruction or viral hepatitis. The patient had a hemoglobin S level of 87.9%, acute renal failure, and mild coagulopathy. Despite the disease severity, he refused exchange transfusion (ET) with packed red blood cells. He was transfused with 2 units of blood and treated mainly with supportive measures. His total bilirubin levels trended down to normal days after discharge. Multiple studies have shown a significant decrease in the mortality rate in SCIC after ET. To date, only two reported adult cases have survived SCIC without aggressive treatment. Our case is the third case that demonstrates recovery of severe SCIC without ET.
S
ickle cell intrahepatic cholestasis (SCIC), one of the syndromes secondary to sickle cell hepatopathy, is a rare but potentially fatal complication of sickle cell disease. Th e pathophysiology results from hepatic ischemia due to intrahepatic obstruction from sickling in the sinusoids (1, 2) . It is characterized by abdominal pain, hepatomegaly, and extreme hyperbilirubinemia with variable transaminase levels (3, 4) . Its clinical course ranges from benign hyperbilirubinemia to fulminant hepatic failure (3, 5) . Benign hyperbilirubinemia is considered self-limited and is characterized by serum bilirubin levels between 10 and 30 mg/ dL. In severe cases, bilirubin levels are usually >30 mg/dL and in some cases >80 mg/dL (3). In fatal cases, renal failure and coagulopathy can develop (5) . Th e only eff ective management for severe SCIC is early exchange transfusion (ET) to reverse liver function (6) (7) (8) . We report the case of a patient with severe SCIC, acute kidney injury, and spontaneous return of bilirubin and hemoglobin S levels to baseline despite refusing red blood cell ET.
CASE REPORT
A 48-year-old man with sickle cell anemia presented with jaundice and mild abdominal pain that had lasted for 1 week. He denied fever, shortness of breath, chest pain, and any change in urine or stool color. His physical exam was unremarkable except for icteric sclerae. Blood analysis was signifi cant for a total bilirubin level of 48.9 mg/dL. His hemoglobin at baseline was 7 g/dL, and hepatitis serology was nonreactive. An ultrasound revealed cholelithiasis without evidence of cholecystitis and choledocholithiasis. Because the patient had taken doxycycline as malaria prophylaxis for a trip to China 2 months earlier, he was initially diagnosed with doxycycline-induced hyperbilirubinemia. His bilirubin level prior to hospital discharge was 50 mg/dL; follow-up in the clinic showed a stable bilirubin level of 50.3 mg/dL.
He was seen 1 week later with increased abdominal pain, fatigue, and fever. Physical examination now revealed mild epigastric and right upper quadrant tenderness and a palpable liver. Blood analysis was signifi cant for a total bilirubin level of 77.5 mg/dL; aspartate aminotransferase, 91 IU/dL; alanine aminotransferase, 31 IU/dL; creatinine, 1.4 mg/dL (an increase from a baseline of 0.8 mg/dL); hemoglobin, 6.5 g/dL; white blood cell count, 13.6 K/uL, with predominant neutrophils; platelets, 400 K/uL; a normal albumin and coagulation panel; alkaline phosphatase, 179 IU/L; and lactate dehydrogenase, 702 U/L. Hemoglobin electrophoresis showed a hemoglobin S of 88.6%. A computed tomography scan of the abdomen confi rmed the fi ndings from the previous ultrasound. Magnetic resonance cholangiopancreatography ruled out an obstruction. Th e patient was diagnosed with intrahepatic cholestasis.
Th e patient refused ET and liver biopsy but accepted intermittent transfusions. He received 2 units of packed red blood cells. His bilirubin level then rose to a maximum level of 78.9 on day 6 of readmission, and his serum creatinine increased to 3.3 mg/dL. Th e next day, the patient developed a myoclonic jerk with normal mental status, which was relieved with clonazepam. His ammonia level and results of magnetic resonance imaging of his brain were normal. Electroencephalography completed while the patient was sleeping showed a slow wave form pattern. His kidney function improved with fl uids and returned to Reversal of liver function without exchange transfusion in sickle cell intrahepatic cholestasis Nattamol Hosiriluck, MD, Supannee Rassameehiran, MD, Erwin Argueta, MD, and Lukman Tijani, MD ( defi ned as >13 mg/dL) (3), a careful physical examination and appropriate laboratory and radiologic studies should be conducted (7, 9) . Liver biopsy was not strongly indicated to establish the diagnosis, since histological fi ndings do not diff er from fi ndings of other sickle cell disease liver involvement (3). In our patient, viral hepatitis and cholelithiasis with cholecystitis were ruled out by negative serology and lack of evidence to suggest extrahepatic obstruction in imaging studies. Hepatic crisis is another common complication of sickle cell disease, characterized by short disease duration (2-3 weeks) with a serum bilirubin level that seldom exceeds 15 mg/dL (1) . Th e development of myoclonic jerks was related to an abnormally high bilirubin level. Normal ammonia levels and lack of altered mentation in this clinical setting made hepatic encephalopathy unlikely.
Q fever may have also contributed to hyperbilirubinemia through two mechanisms. First, infection can trigger the development of SCIC (1). Second, the disease itself can cause an increase in bilirubin levels. However, studies have shown that only one-third of Q fever patients develop hyperbilirubinemia, and the highest serum bilirubin level reported was 18.7 mg/dL (10). Th erefore, Q fever itself was not the major cause of extreme hyperbilirubinemia in this case. SCIC has an overall mortality rate of over 50% (3, 11) . Th e only known eff ective management is ET to lower hemoglobin S levels to <30% (8). Ahn et al (3) conducted a literature review that compared two groups of 44 patients from 1953 to 2002 according to the degree of hepatic dysfunction. Th ere were 16 adult cases in the study (those >18 years), 15 of whom were in the severe group, with a mean maximum bilirubin level of 76.8 mg/dL (opposed to 36.2 mg/dL in the mild baseline. Broad-spectrum intravenous antibiotics were initiated early in the hospital stay and were subsequently deescalated to oral moxifl oxacin. Cultures came back as negative, as did HIV, syphilis, and leptospirosis serology results, but IgG results for Q fever were positive in both phase I and II. Bilirubin trended down to a range of 50 to 60 mg/dL before discharge from the current hospital admission (Table 1) . Outpatient follow-up showed a normal bilirubin level in a 2-month period (Figure 1) . After being discharged from the hospital, the patient remained asymptomatic and now continues with his regular clinic visits.
DISCUSSION
Sheehy fi rst categorized sickle cell hepatopathy in 1977 into fi ve clinical syndromes: viral hepatitis, hepatitis crisis, cirrhosis, cholelithiasis with cholecystitis, and intrahepatic cholestasis (SCIC). Th e clinical manifestations of each entity are similar, including fever, right upper quadrant pain, and jaundice. Th ere was no suggested guideline for diagnosis and treatment of SCIC. When a patient presents with extreme hyperbilirubinemia Figure 1 . Hemoglobin, bilirubin, and hemoglobin S level in relation to hospital course.
Baylor University Medical Center Proceedings Volume 27, Number 4 group). Th e mortality rate in the two groups was 4% and 64%, respectively. One death was reported among fi ve patients who received ET, while 9 deaths were reported among 10 patients who underwent supportive treatment. Th is fi nding supports the evidence that ET can signifi cantly reduce the mortality rate of SCIC. Recent case reports have confi rmed the successful outcome with ET. Eight adult cases (5, (11) (12) (13) (14) (15) (16) (Table 2 ). Seven out of the eight patients received ET, and two of them progressed to hepatic failure and death (5, 13) . Two of the patients continued to receive regular ET to maintain their hemoglobin S level (14, 16) . Overall, there are 24 case reports in the adult population. Th e mortality rate among those who received ET was 25% (3 deaths among 12 patients), compared with 83% in the supportive group (10 deaths among 12 patients). Only two reported cases (17, 18) survived SCIC without ET. One case presented as mild, selflimited hyperbilirubinemia (17) . Th e other presented with severe anemia, with a hemoglobin of 2.8 g/dL and hepatic and renal failure (18) . Th e patient was treated with packed red blood cells and plasma transfusions to correct anemia and coagulopathy. He then had reversal of organ failure within 48 hours of admission. Our case represents a third known case report of SCIC in an adult who had a favorable outcome with supportive treatment. 
